At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 64 enrolled
Drug / intervention
Tremelimumab monotherapy +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients With Advanced Solid Tumors
In Brief
A Phase 2 clinical trial evaluating Tremelimumab monotherapy, MEDI4736 monotherapy, and 1 other intervention for Urothelial Bladder Cancer and 2 related conditions. Completed, enrolled 64 participants across 14 sites in 5 countries.
Detailed Summary
A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients with Advanced Solid Tumors
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrothelial Bladder Cancer, Triple-negative Breast Cancer, Pancreatic Ductal Adenocarcinoma
CountriesBelgium, Netherlands, Poland, South Korea, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 2015
Enrollment StartNov 2015
Primary CompletionFeb 2018
Study CompletionMar 2023
TodayJul 2026
First PostedAug 19, 2015
Enrollment StartNov 2, 2015
Primary CompletionFeb 17, 2018
Study CompletionMar 28, 2023
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 10.9 years ago
Interventions
Tremelimumab monotherapybiological
IV infusion
MEDI4736 monotherapybiological
IV infusion
MEDI4736 + tremelimumab combination therapybiological
IV infusion